<i>MiR-29a</i>: a potential therapeutic target and promising biomarker in tumors

Wang, Jinyan; Zhang, Qian; Wang, Dandan; Yan, Wei; Sha, Huanhuan; Zhao, Jinmin; Yang, Su-Jin; Zhang, Heda; Hou, Jianglong; Xu, Hanzi; He, Yunjie; Hu, Jia-hua; Zhong, Shanliang; Tang, Jinhai

doi:10.1042/bsr20171265

Cited by 62 publications

(49 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In WT, there are few studies that have reported it; one of them evaluated its expression in eight serum samples from WT patients and in eight predominantly blastemal FHWT tumors, and in both cases, no changes in its expression were observed, likely due to a low sample number (3,31). In other tumors, its expression has been reported low as in renal cell carcinoma (32), lung cancer (33), and hepatocellular carcinoma (23); moreover, overexpression of this miRNA in these tumors inhibits cell proliferation, migration, and invasion, leading to it being characterized as a tumor suppressor.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA Profiling in Wilms Tumor: Identification of Potential Biomarkers

et al. 2020

View full text Add to dashboard Cite

Wilms tumor (WT) is the most frequently diagnosed malignant renal tumor in children. With current treatments, ∼90% of children diagnosed with WT survive and generally present with tumors characterized by favorable histology (FHWT), whereas prognosis is poor for the remaining 10% of cases where the tumors are characterized by cellular diffuse anaplasia (DAWT). Relatively few studies have investigated microRNA-related epigenetic regulation and its relationship with altered gene expression in WT. Here, we aim to identify microRNAs differentially expressed in WT and describe their expression in terms of cellular anaplasia, metastasis, and association with the main genetic alterations in WT to identify potential prognostic biomarkers. Expression profiling using TaqMan low-density array was performed in a discovery cohort consisting of four DAWT and eight FHWT samples. Relative quantification resulted in the identification of 109 (48.7%) microRNAs differentially expressed in both WT types. Of these, miR-10a-5p, miR-29a-3p, miR-181a-5p, miR-200b-3p, and miR-218-5p were selected and tested by RT-qPCR on a validation cohort of 53 patient samples. MiR-29a and miR-218 showed significant differences in FHWT with low (P = 0.0018) and high (P = 0.0131) expression, respectively. To discriminate between miRNA expression FHWTs and healthy controls, the receiver operating characteristic (ROC) curves were obtained; miR-29a AUC was 0.7843. Furthermore, low expression levels of miR-29a and miR-200b (P = 0.0027 and P = 0.0248) were observed in metastatic tumors. ROC curves for miR-29a discriminated metastatic patients (AUC = 0.8529) and miR-200b (AUC = 0.7757). To confirm the differences between cases with poor prognosis, we performed in situ hybridization for three microRNAs in five DAWT and 17 FHWT samples, and only significant differences between adjacent tissues and FHWT tumors were found for miR-181a, miR-200b, and miR-218, in both total pixels and nuclear analyses. Analysis of copy number variation in genes showed that the most prevalent alterations were WTX (47%), IGF2 (21%), 1q (36%) gain, 1p36 (16%), and WTX deletion/1q duplicate (26%). The five microRNAs evaluated are involved in the Hippo signaling pathway and participate in Wilms tumor development through their effects on differentiation, proliferation, angiogenesis, and metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA Profiling in Wilms Tumor: Identification of Potential Biomarkers

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Therefore, in the present study experimental animals were exposed to DMBA and the expression levels of miR-330, miR-29a, miR-9-1, miR-9-3 were examined. These miRNAs have already been reported to exhibit altered expression in several malignant tumors and through different signaling pathways they play a role in the regulation of oncogenes or tumor suppressor genes, cell growth, proliferation, invasion, migration, metastasis or apoptosis (21)(22)(23)(24)(25)(26). Besides the mentioned microRNAs, we also examined the expression of the mTORC1 gene.…”

mentioning

confidence: 99%

Effect of 7,12-Dimethylbenz(α)anthracene on the Expression of miR-330, miR-29a, miR-9-1, miR-9-3 and the mTORC1 Gene in CBA/Ca Mice

Tomesz

Szabó

Molnar

et al. 2020

In Vivo

View full text Add to dashboard Cite

Background/Aim: Development of malignant tumors is preceded by molecular biological events. Our aim was to establish an assay panel by using miRNAs and other genes for the rapid screening of potential carcinogens or chemopreventive agents. Materials and Methods: Six male and 6 female CBA/Ca mice received 20 mg/bwkg 7,12dimethylbenz(α)anthracene (DMBA) intraperitoneally, and 24 h later RNA was isolated from parenchymal organs. Expression of miR-330, miR-29a, miR-9-1, miR-9-3 and mTORC1 was analysed by real time polymerase chain reaction and compared to non-treated controls. Results: DMBA caused significant alterations in the expression of the studied genes. The most profound changes were the strongly elevated miR-9-3 and mTORC1 expressions in female mice in all organs studied. Conclusion: miR-9-3 and mTORC1 expression in female mice were found to be the most suitable biomarkers for rapid identification of possible carcinogenic effects. According to estimates, in 2018 there were 18.1 million new malignant cancer cases and 9.6 million cancer deaths (1). According to WHO data, 30-50 % of all malignant tumors could be prevented (2), and early diagnosis would usually increase the chance of successful treatment.

show abstract

“…As a member of the miR-29 family, miR-29a is considered to play a crucial role in the regulation of multiple cancers ( Wang et al, 2018 ). It was up-regulated and promoted epithelial-mesenchymal transition, migration and invasion in breast cancer cells ( Wu et al, 2019 ).…”

Section: Discussionmentioning

confidence: 99%

miR-29a-3p directly targets Smad nuclear interacting protein 1 and inhibits the migration and proliferation of cervical cancer HeLa cells

Chen

Zhang

Yan

et al. 2020

PeerJ

View full text Add to dashboard Cite

Smad nuclear interacting protein 1 (SNIP1) is a nuclear protein and involved in essential biological processes. MicroRNAs are effective regulators of tumorigenesis and cancer progression via targeting multiple genes. In present study, we aimed to investigate the function of SNIP1 and identify novel miRNA-SNIP1 axis in the development of cervical cancer. The results showed for the first time that silencing of the SNIP1 gene inhibited the migration and proliferation in HeLa cells significantly. Bioinformatics analysis and dual luciferase reporter assay demonstrated that miR-29a-3p could target 3′ UTR of SNIP1 directly. The mRNA and protein expression levels of SNIP1 were negative regulated by miR-29a-3p according to the RT-qPCR and Western blot analysis, respectively. Furthermore, functional studies showed that over-expression of miR-29a-3p restrained HeLa cells migration and proliferation, and the mRNA expression of SNIP1 downstream genes (HSP27, c-Myc, and cyclin D1) were down-regulated by miR-29a-3p. Together, we concluded that miR-29a-3p suppressed the migration and proliferation in HeLa cells by directly targeting SNIP1. The newly identified miR-29a-3p/SNIP1 axis could provide new insight into the development of cervical cancer.

show abstract

MiR-29a: a potential therapeutic target and promising biomarker in tumors

Cited by 62 publications

References 97 publications

MicroRNA Profiling in Wilms Tumor: Identification of Potential Biomarkers

MicroRNA Profiling in Wilms Tumor: Identification of Potential Biomarkers

Effect of 7,12-Dimethylbenz(α)anthracene on the Expression of miR-330, miR-29a, miR-9-1, miR-9-3 and the mTORC1 Gene in CBA/Ca Mice

miR-29a-3p directly targets Smad nuclear interacting protein 1 and inhibits the migration and proliferation of cervical cancer HeLa cells

Contact Info

Product

Resources

About